HEMOSTEMIX ANNOUNCES ACP-01 TREATMENT-PURCHASE AVAILABLE WITH SOCIAL MEDIA CAMPAIGN UNDERWAY Read More
Hemostemix Announces the Incorporation of PreCerv Inc. and a Global Field of Use License to NCP-01 Read More
Investor Relations Hemostemix Announces the Incorporation of Hemostemix PR Inc: 50% reimbursement of R&D expenses in cash Read More
Investor Relations Hemostemix Presents at Puerto Rico Investor Summits: Showcasing Global Scale-Up Strategy and Economic Impact Read More
